These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

760 related items for PubMed ID: 28364245

  • 41. Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy.
    Koo T, Wood MJ.
    Hum Gene Ther; 2013 May; 24(5):479-88. PubMed ID: 23521559
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
    Anthony K, Arechavala-Gomeza V, Ricotti V, Torelli S, Feng L, Janghra N, Tasca G, Guglieri M, Barresi R, Armaroli A, Ferlini A, Bushby K, Straub V, Ricci E, Sewry C, Morgan J, Muntoni F.
    JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
    [Abstract] [Full Text] [Related]

  • 45. Restoring Dystrophin Expression with Exon 44 and 53 Skipping in the DMD Gene in Immortalized Myotubes.
    Echigoya Y, Yokota T.
    Methods Mol Biol; 2023 Jan; 2587():125-139. PubMed ID: 36401027
    [Abstract] [Full Text] [Related]

  • 46. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
    Wang Q, Yin H, Camelliti P, Betts C, Moulton H, Lee H, Saleh AF, Gait MJ, Wood MJ.
    J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy.
    Wilton SD, Fletcher S.
    Curr Pharm Des; 2010 Apr; 16(8):988-1001. PubMed ID: 20041827
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Morpholino oligonucleotide-mediated exon skipping for DMD treatment: Past insights, present challenges and future perspectives.
    Gupta S, Sharma SN, Kundu J, Pattanayak S, Sinha S.
    J Biosci; 2023 Apr; 48():. PubMed ID: 37846020
    [Abstract] [Full Text] [Related]

  • 57. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C, Tuffery-Giraud S, Matsuo M, Hamroun D, Humbertclaude V, Monnier N, Moizard MP, Voelckel MA, Calemard LM, Boisseau P, Blayau M, Philippe C, Cossée M, Pagès M, Rivier F, Danos O, Garcia L, Claustres M.
    Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Exon Skipping Using Antisense Oligonucleotides for Laminin-Alpha2-Deficient Muscular Dystrophy.
    Hara Y, Mizobe Y, Miyatake S, Takizawa H, Nagata T, Yokota T, Takeda S, Aoki Y.
    Methods Mol Biol; 2018 Feb; 1828():553-564. PubMed ID: 30171567
    [Abstract] [Full Text] [Related]

  • 60. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.
    Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T, Duguez SM, Nagaraju K, Hoffman EP, Partridge T, Takeda S.
    Proc Natl Acad Sci U S A; 2012 Aug 21; 109(34):13763-8. PubMed ID: 22869723
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.